Literature DB >> 21810174

TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?

Michael J Strong1, Kathryn Volkening.   

Abstract

TAR DNA binding protein of 43 kDa (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) have recently been linked to the pathology of amyotrophic lateral sclerosis (ALS). These proteins share many common features that include interaction with either DNA or RNA, participation in the formation of RNP complexes, the formation of pathological aggregates in degenerating motor neurons in ALS, and the ability to impact the RNA metabolism pathway at multiple levels from transcription to translation. Coupled with the observation that mutations in either TDP-43 or FUS/TLS are associated with ALS, this provides further support for the integral role of altered RNA metabolism in ALS.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810174     DOI: 10.1111/j.1742-4658.2011.08277.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  14 in total

1.  The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.

Authors:  Claudia Fallini; Gary J Bassell; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2012-05-28       Impact factor: 6.150

Review 2.  TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Robert H Baloh
Journal:  FEBS J       Date:  2011-08-24       Impact factor: 5.542

Review 3.  Dendritic protein synthesis in the normal and diseased brain.

Authors:  S A Swanger; G J Bassell
Journal:  Neuroscience       Date:  2012-12-20       Impact factor: 3.590

4.  Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype.

Authors:  Kathryn Volkening; Sali M K Farhan; Jessica Kao; Cheryl Leystra-Lantz; Lee Cyn Ang; Adam McIntyre; Jian Wang; Robert A Hegele; Michael J Strong
Journal:  Mol Cell Biochem       Date:  2021-03-04       Impact factor: 3.396

5.  Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions.

Authors:  Shinsuke Ishigaki; Akio Masuda; Yusuke Fujioka; Yohei Iguchi; Masahisa Katsuno; Akihide Shibata; Fumihiko Urano; Gen Sobue; Kinji Ohno
Journal:  Sci Rep       Date:  2012-07-24       Impact factor: 4.379

Review 6.  Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction.

Authors:  Lucas M Bronicki; Bernard J Jasmin
Journal:  RNA       Date:  2013-08       Impact factor: 4.942

7.  Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.

Authors:  Christophe Verbeeck; Qiudong Deng; Mariely Dejesus-Hernandez; Georgia Taylor; Carolina Ceballos-Diaz; Jannet Kocerha; Todd Golde; Pritam Das; Rosa Rademakers; Dennis W Dickson; Thomas Kukar
Journal:  Mol Neurodegener       Date:  2012-10-10       Impact factor: 14.195

8.  TLS/FUS: a protein in cancer and ALS.

Authors:  Adelene Y Tan; James L Manley
Journal:  Cell Cycle       Date:  2012-08-23       Impact factor: 4.534

9.  FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD.

Authors:  Yusuke Fujioka; Shinsuke Ishigaki; Akio Masuda; Yohei Iguchi; Tsuyoshi Udagawa; Hirohisa Watanabe; Masahisa Katsuno; Kinji Ohno; Gen Sobue
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Senataxin protects the genome: Implications for neurodegeneration and other abnormalities.

Authors:  Martin F Lavin; Abrey J Yeo; Olivier J Becherel
Journal:  Rare Dis       Date:  2013-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.